You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

209 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.
Mar 2024
Drug
Other Name(s): Xpovio®
Mar 2024
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
Guidelines and Advice
Drug
Other Name(s): Lynparza®
Jan 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Drug
Other Name(s): Padcev®
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Jan 2025
Drug
Other Name(s): Columvi®
Jan 2025
Drug
Other Name(s): Epkinly™
Jan 2025
Drug
Other Name(s): Tecvayli®
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025

Pages